Introduction
============

A clear trend has been observed toward increase in frozen-thawed embryo transfers (FETs) \[[@b1-yujm-2019-00346]\]. It might be due to the increase in the live birth rates with FET when compared with fresh transfers and improved perinatal outcomes in FET \[[@b2-yujm-2019-00346]\]. Suggested mechanisms of the benefits of FET are the synchrony of embryo-endometrial development and the physiological concentration of estradiol and progesterone in the FET cycle. In fresh embryo transfer cycle, the concentrations of estradiol and progesterone surpass the physiologic levels of normal menstrual cycle or the FET cycle.

The freeze-all policy was introduced based on these findings \[[@b3-yujm-2019-00346]\]. Originally, the freeze-all policy was based on the segmentation of in vitro fertilization (IVF) treatment with the use of a gonadotropin-releasing hormone (GnRH) antagonist protocol, GnRH agonist triggering, the elective cryopreservation of all embryos by vitrification, and FET in the subsequent cycle \[[@b4-yujm-2019-00346]\].

Although the freeze-all policy might be a promising new method to overcome the old problems in the IVF procedure, there are some weaknesses and threats. In poor responders, the embryos may not be developed to an appropriate stage of freezing. In such cases, clinicians may not retrieve any embryos for transfer and it would affect the confidence between the patients and the clinicians. Moreover, the exact parameters related with the pregnancy rate in the FET cycle are unclear. Therefore, it is important to predict the possibility of acquisition of good quality embryos and the pregnancy rates of the FET cycle.

In a recent study, characteristics of high-quality embryos, endometrial preparation protocol, number of transferred embryos, and body mass index of the patients independently affected the live birth rate in FET \[[@b5-yujm-2019-00346]\]. However, in case of the freeze-all policy, all embryos are frozen and fresh embryo transfer is not performed. Hence, the parameters primarily related with the pregnancy rate are unclear.

In this study, we analyzed the differences in various clinical parameters in the freeze-all policy between the pregnant group and the non-pregnant group through a single cycle of controlled ovarian stimulation (COS) composed of 3 cycles of FET.

Materials and methods
=====================

1. Ethics statement
-------------------

The present study was approved by the Institutional Review Committee of Pusan National University Hospital (IRB No. H-1908-021-082). Eighty-nine infertile women qualified as normal responders were recruited for this study and provided informed consent. The informed consent included the benefits and the threats of the freeze-all policy.

2. Patients
-----------

This study was retrospectively conducted from January 2015 to December 2016 at the Infertility Center, Pusan National University Hospital. A normal responder was defined as having the following criteria: (1) age \<40 years, (2) follicle stimulating hormone level \<12 mIU/mL at cycle day 2 or 3 and, (3) anti-Müllerian hormone level \>1 ng/mL.

Patients having inappropriate endometrium for implantation, which included conditions such as endometrial synechiae, unresponsive thin endometrium, or abnormal anatomy of the uterine cavity, were excluded. After infertility workups, endometrial and/or tubal corrective surgeries were performed after COS and before FET in indicated cases. This study was conducted through a single cycle of COS composed of 3 cycles of FET.

3. Preparing the blastocyst and the endometrium for frozen-thawed embryo transfer
---------------------------------------------------------------------------------

We adopted the routine protocol of our clinics for COS, the blastocyst culture, and the preparation of the endometrium \[[@b6-yujm-2019-00346]\]. The infertile women individually received the GnRH antagonist protocol or the GnRH agonist long protocol. For triggering, human chorionic gonadotropin (hCG) (Ovidrel 5,000--10,000 IU; Merck Serono, Geneva, Switzerland) or a GnRH agonist (decapeptyl 0.2 mg; Ferring, Saint-Prex, Switzerland) was used. All fertilized embryos were cultured to the blastocyst stage in sequential G1/G2 media (Vitrolife, Gothenburg, Sweden). Good quality embryos having appropriate morphology of the trophectoderm and inner cell mass and fewer fragmentations of blastomeres were selected and vitrified for elective FET. Two to 3 months after the oocyte pick up, oral estradiol valerate was administered in gradually increasing quantity for endometrial preparation (progynova 2--6 mg/day; Bayer Schering Pharma, Berlin, Germany) after pituitary luteal down-regulation with preliminary GnRH agonist (lucrin, 0.1 mg/day; Abbott, Chicago, IL, USA). At menstrual day 15, endometrial thickness (EMT) was evaluated. In cases with EMT over 7--8 mm, vaginal progesterone gel (Crinone 90 mg/day; Merck Serono) and oral estradiol valerate were administered for inducing the secretory phase of the endometrium. In cases where EMT did not reach 7 mm, oral estradiol valerate was administered continuously and EMT was rechecked later. Vaginal progesterone was administered after EMT was confirmed to be suitable. Blastocysts were warmed and transferred under transabdominal ultrasound guidance using a soft embryo transfer catheter (Cook Medical, Spencer, IN, USA).

4. Outcome measures and following procedures
--------------------------------------------

Twelve days after the embryo transfer, serum β-hCG was checked for confirmation of pregnancy. Progesterone support was continued until 10 gestational weeks in women who conceived. In the non-pregnant group, a second embryo transfer or a second COS cycle was conducted ([Fig. 1](#f1-yujm-2019-00346){ref-type="fig"}).

5. Statistical analyses
-----------------------

All patients were retrospectively divided into the pregnant and the non-pregnant groups after FET. The variables under study were compared between the two groups by Wilcoxon rank sum test for independent samples using PASW version 18.0 (SPSS Inc., Chicago, IL, USA). The data were expressed as mean±standard deviation unless specified otherwise. The value of *p*\<0.05 was considered statistically significant.

Results
=======

In this study, we analyzed the difference in various clinical parameters in the freeze-all policy between the pregnant group and the non-pregnant group through a single cycle of COS composed of 3 cycles of FET.

Totally, 153 FETs were carried out in 89 patients ([Fig. 1](#f1-yujm-2019-00346){ref-type="fig"}). Patient characteristics and outcomes of COS are presented in [Table 1](#t1-yujm-2019-00346){ref-type="table"}. After the first FET cycle, 35 patients (39.3%) became pregnant. [Table 2](#t2-yujm-2019-00346){ref-type="table"} shows the comparison of parameters between the pregnant group and the non-pregnant group after the first FET cycle. Significant differences were observed in the number of matured oocytes, the number of fertilized oocytes, the number of frozen blastocysts, and the number of transferred embryos between the two groups. Among the 35 pregnant patients, 2 patients (5.7%) had a spontaneous abortion and 2 patients (5.7%) experienced chemical pregnancy. The second FET cycle was carried out in 50 patients. Fourteen patients (28.0%) became pregnant after the second cycle. Among these 14 pregnant patients, 3 patients (21.4%) experienced chemical pregnancy and 1 patient (7.1%) was diagnosed with a missed abortion.

[Table 3](#t3-yujm-2019-00346){ref-type="table"} shows the comparison of parameters between the pregnant group and the non-pregnant group after all FET cycles. Through a single cycle of COS that consisted of 3 cycle of FET, 52 patients became pregnant, while 37 patients did not become pregnant. Significant differences were observed in the number of matured oocytes, the number of fertilized oocytes, the number of frozen blastocysts, and the number of transferred embryos. In particular, the number of frozen blastocysts in the pregnant group was almost twice that in the non-pregnant group (5.6±3.1 vs. 2.8±1.9, *p*\<0.001).

[Fig. 2](#f2-yujm-2019-00346){ref-type="fig"} shows the area under curve (AUC) of the receiver operating characteristic (ROC) curve for the number of matured oocytes, fertilized oocytes, and frozen blastocysts in the cumulative pregnancy cycle ([Fig. 2A](#f2-yujm-2019-00346){ref-type="fig"}) and in the pregnancy cycle after the first FET ([Fig. 2B](#f2-yujm-2019-00346){ref-type="fig"}). The AUC of the ROC curve in the cumulative pregnancy group was 0.801 for the 4 frozen blastocysts (95% confidence interval \[CI\], 0.625--0.819), 0.713 for the 13 fertilized oocytes (95% CI, 0.540--0.747), and 0.710 for the 8 matured oocytes (95% CI, 0.525--0.733) ([Fig. 2A](#f2-yujm-2019-00346){ref-type="fig"}). The AUC of the ROC curve in the pregnancy group after the first FET cycle was 0.730 for the 4 frozen blastocysts (95% CI, 0.588--0.788), 0.649 for the 13 fertilized oocytes (95% CI, 0.548--0.753), and 0.634 for the 14 matured oocytes (95% CI, 0.524--0.733) ([Fig. 2B](#f2-yujm-2019-00346){ref-type="fig"}). The AUC of the ROC curve for the 4 frozen blastocysts was 0.801 in the pregnant group.

Discussion
==========

This study was conducted to investigate the factors that affect the pregnancy rates of the FET cycle in the freeze-all policy. We analyzed the difference in various clinical parameters in the freeze-all policy between the pregnant group and the non-pregnant group through a single cycle of COS composed of 3 cycles of FET. And carried out the freeze-all policy in the normal responders after informed consent was obtained from the patients. Currently, FET is being performed in extra frozen embryos due to the legislation changes such as medical insurance coverage in South Korea.

Introduction of vitrification and development of GnRH antagonist protocol are the foundations of the freeze-all policy. Vitrification as a method of cryopreservation of embryos improved the survival rate of thawing embryos. By using GnRH agonist triggering in the GnRH antagonist protocol, the ovarian hyperstimulation syndrome (OHSS) risk is almost removed from the assisted reproductive technology procedure \[[@b3-yujm-2019-00346]\].

Apart from the decreased risk of OHSS, the freeze-all policy has several strengths. A meta-analysis comparing the fresh transfers and the FET cycles showed significantly higher implantation rates and clinical and ongoing pregnancy rates in the FET cycles \[[@b7-yujm-2019-00346]\]. The suggested mechanisms for the poor clinical outcomes in the fresh cycles are abnormal hormonal milieu and the suboptimal endometrial development in the COS cycles \[[@b4-yujm-2019-00346]\]. Moreover, the rate of ectopic pregnancy is reduced \[[@b8-yujm-2019-00346],[@b9-yujm-2019-00346]\] and better perinatal outcomes have been reported in FET cycles \[[@b10-yujm-2019-00346],[@b11-yujm-2019-00346]\].

However, there are several critical opinions about the freeze-all policy. A meta-analysis about the results of the freeze-all policy included only three small studies and the total number of patients included in the analysis was only 633 \[[@b12-yujm-2019-00346]\]. The studies included in this meta-analysis were highly heterogeneous in terms of the types of patients and some of the technical aspects \[[@b12-yujm-2019-00346]\]. To confirm the advantages of the freeze-all policy, further large-scale research with homogeneous criteria is needed.

There are some obstacles to the adaptation of the freeze-all policy to the real clinical practice. The policy needs changes in the current IVF practice and optimization of the cryopreservation techniques \[[@b4-yujm-2019-00346]\]. In an institute having suboptimal culture techniques, the possibility of cancellation of embryo transfer after COS would be increased. To apply the freeze-all policy to general infertility clinics, it has to be preceded by quality control of the culture technique. After quality control, the strengths of the freeze-all policy, such as better pregnancy rates and lower ectopic pregnancy rates, could be achieved, particularly in normal responders. Moreover, the freeze-all policy is a cost-effective strategy when compared to the fresh embryo transfer \[[@b13-yujm-2019-00346]\]. Thus, if adequate number of oocytes or embryos were retrieved, the freeze-all policy is a better option than the fresh embryo transfer in normal responders.

In this study, the AUC of the ROC curve was 0.801 for cumulative pregnancy group when the cut-off value of the number of frozen blastocysts was 4. To the best of our knowledge, there has been no report suggesting the cut-off value for the freeze-all policy as a predictive parameter for pregnancy.

The outcomes of IVF could be different in low or poor responders. Roque et al. \[[@b14-yujm-2019-00346]\] reported that the freeze-all policy may be related to better IVF outcomes in normal responders, but these potential advantages decrease with worsening ovarian response. In patients with 4--9 oocytes retrieved, the implantation rate and the ongoing pregnancy rate showed no difference between the fresh embryo transfer and the FET group. Meanwhile, patients with 10--15 retrieved oocytes showed significant differences in the implantation rate and the ongoing pregnancy rate between the fresh transfer group and the FET group. The FET group showed better outcomes (implantation rate of 30.1% in the FET group and 22.1% in the fresh embryo transfer, *p*=0.028; ongoing pregnancy rate of 47% in the FET group and 34% in the fresh embryo transfer, *p*=0.021). Moreover, in poor responders, cycle cancellation rates could be increased.

On the contrary, the strengths of the freeze-all policy such as better pregnancy rates and perinatal outcomes and lesser ectopic pregnancy rates might also be similar for the poor responders. In case of the poor responders who need uterine surgery for improving the possibility of implantation, the freeze-all policy could avoid unnecessary operation. Usually, in older age groups, increased incidence of benign uterine disease is observed and the chances of poor response to COS are increased. If an adequate number of embryos could be obtained, gynecologic operation could be conducted after freezing all the embryos. In case of failure to obtain adequate embryos, benign uterine disease could be managed by other treatment modalities. The freeze-all policy is also suitable for preimplantation genetic testing, which is applied more commonly in the older age group. Hence, the freeze-all policy could have several advantages in normal as well as poor responders.

This study suggested a cut-off value of the number of oocytes and blastocysts for the pregnant group in the freeze-all policy. However, there are critical limitations to this study. The number of patients included in this study was relatively small, and the study was carried out retrospectively. The possible causes of repeated implantation failure, such as intrauterine adhesion and thin endometrium were considered in the exclusion criteria. However, the factors associated with immunologic or thrombotic tendencies were not included in the screening. In addition, a dramatic decrease was observed in the pregnancy rates in the second cycle of FET. This finding may be because the embryos with poorer quality than those from the first cycle had been transferred. Only the good quality embryos were frozen according to the morphological criteria. However, the quality of the embryos in the same grade of the morphological criteria may vary. All embryos were cultured to the blastocyst stage at our center. Hence, information about the prediction of pregnancy in day 3 embryo transfer could not be obtained.

Despite these limitations, this study might provide significant information about the predictive value of clinical parameters and results of COS for pregnancy rates in the freeze-all policy.

In this study, we confirmed that the number of matured oocytes, fertilized oocytes, and frozen blastocysts might be predictive factors for pregnancy in the freeze-all policy.

No potential conflict of interest relevant to this article was reported.

**Funding**

This work was supported by clinical research grant from Pusan National University Hospital in 2019.

![Flow diagram of the inclusion cycles. In this study, 153 embryo transfer cycles in 89 infertile women were analyzed. The second FET cycle was conducted in 50 patients and the third FET cycle was conducted in 14 patients. In case of no remnant frozen embryos, a second COS was started. FET, frozen-thawed embryo transfer; COS, controlled ovarian stimulation.](yujm-2019-00346f1){#f1-yujm-2019-00346}

![ROC curve of the cumulative pregnancy group (A) and the pregnancy group after the first frozen embryo transfer (B). (A) AUC of the ROC curve of the cumulative pregnancy group: 0.801 for the 4 frozen blastocysts (95% CI, 0.625--0.819), 0.713 for the 13 fertilized oocytes (95% CI, 0.540--0.747), and 0.710 for the 8 matured oocytes (95% CI, 0.525--0.733). (B) AUC of the ROC curve of the pregnancy group for the first frozen embryo transfer: 0.730 for the 4 frozen blastocysts (95% CI, 0.588--0.788), 0.649 for the 13 fertilized oocytes (95% CI, 0.548--0.753), and 0.634 for the 14 matured oocytes (95% CI, 0.524--0.733). ROC, receiver operating characteristic; AUC, area under curve; CI, confidence interval.](yujm-2019-00346f2){#f2-yujm-2019-00346}

###### 

Patients characteristics and COS outcomes

  Characteristic                 Value
  ------------------------------ -----------------
  Patient                        89 (100)
  Age (yr)                       33.6±3.6
  BMI (kg/m^2^)                  22.9±3.7
  Primary infertility            52 (58.4)
  Secondary infertility          37 (41.6)
  Duration of infertility (mo)   47.1±30.5
  Basic laboratory finding       
   FSH (mIU/mL)                  6.9±4.6
   LH (mIU/mL)                   8.1±13.8
   Prolactin (ng/mL)             15.9±9.4
   AMH (ng/mL)                   5.2±4.1
  COS outcome                    
   Total dose of FSH (IU)        3,056.0±1,102.9
   Total dose of LH (IU)         1,229.8±1,178.3
   Oocytes retrieved             14.1±6.9
   Oocytes matured               11.4±6.1
   Oocytes fertilized            10.3±5.6
   Blastocysts frozen            4.4±3.0

Values are presented as number (%) or mean±standard deviation.

COS, controlled ovarian stimulation; BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; AMH, anti-Müllerian hormone.

###### 

Clinical and COS parameters according to pregnancy or not after first FET

  Clinical and COS parameter     Pregnant group (n=35)   Non-pregnant group (n=54)   *p*-value
  ------------------------------ ----------------------- --------------------------- ---------------------------------------------------------
  Primary infertility            18 (51.4)               34 (63.0)                   0.105^[a)](#tfn3-yujm-2019-00346){ref-type="table-fn"}^
  Secondary infertility          17 (48.6)               20 (37.0)                   
  Age (yr)                       33.5±3.4                33.7±3.8                    0.987
  BMI (kg/m^2^)                  22.4±3.2                23.1±3.9                    0.457
  Duration of infertility (mo)   40.5±28.6               51.3±31.2                   0.103
  Basic laboratory finding                                                           
   FSH (mIU/mL)                  7.0±4.5                 6.8±4.7                     0.564
   LH (mIU/mL)                   8.5±15.7                7.9±12.6                    0.253
   Prolactin (ng/mL)             16.6±11.6               15.5±7.7                    0.920
   AMH (ng/mL)                   4.7±3.5                 5.65±4.6                    0.591
  COS outcome                                                                        
   Total dose of FSH (IU)        3,034.3±1,119.8         3,070.0±1,102.2             0.468
   Total dose of LH (IU)         1,125.0±865.5           1,295.6±1,342.0             0.492
   Oocytes retrieved             15.6±7.1                13.1±6.7                    0.107
   Oocytes matured               13.1±6.6                10.3±5.5                    0.037
   Oocytes fertilized            12.1±6.4                9.1±4.8                     0.020
   Blastocysts frozen            6.1±3.5                 3.4±2.0                     \<.0.001
   Blastocysts transferred       2.1±0.1                 1.7±0.1                     0.009

Values are presented as number (%) or mean±standard deviation.

COS, controlled ovarian stimulation; FET, frozen embryo transfer; BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; AMH, anti-Müllerian hormone.

Wilcoxon rank sum test.

Fisher exact test.

###### 

Clinical and COS parameters according to pregnancy or not after all FET

  Clinical and COS parameter           Pregnant group (n=52)   Non-pregnant group (n=37)   *p*-value
  ------------------------------------ ----------------------- --------------------------- ---------------------------------------------------------
  Primary infertility                  30 (57.7)               22 (59.5)                   0.784^[a)](#tfn5-yujm-2019-00346){ref-type="table-fn"}^
  Secondary infertility                22 (42.3)               15 (40.5)                   
  Age (yr)                             33.3±3.4                34.0±3.9                    0.677
  BMI (kg/m^2^)                        22.9±4.0                22.8±3.1                    0.836
  Duration of infertility (mo)         44.3±29.6               51.1±31.7                   0.339
  Basic laboratory findings                                                                
   FSH (mIU/mL)                        7.1±4.4                 6.6±5.0                     0.307
   LH (mIU/mL)                         8.1±14.3                8.1±13.3                    0.245
   Prolactin (ng/mL)                   16.3±10.1               15.3±8.3                    0.666
   AMH (ng/mL)                         5.4±4.1                 4.9±4.3                     0.439
  COS outcome                                                                              
   Total dose of FSH (IU)              3,008.2±948.6           3,123.1±1,300.4             0.767
   Total dose of LH (IU)               1,109.4±946.0           1,995.0±1,436.1             0.857
   Oocytes retrieved                   15.4±6.8                12.3±6.7                    0.031
   Oocytes matured                     12.9±6.1                9.2±5.4                     0.006
   Oocytes fertilized                  11.8±5.8                8.2±4.7                     0.004
   Blastocysts frozen                  5.6±3.1                 2.8±1.9                     \<0.001
   Number of blastocysts transferred   2.0±0.5                 1.7±0.5                     0.001

Values are presented as number (%) or mean±standard deviation.

COS, controlled ovarian stimulation; FET, frozen embryo transfer; BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; AMH, anti-Müllerian hormone.

Wilcoxon rank sum test.

Fisher exact test.
